Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis Benefiber Powder Supplement Debuting In March

This article was originally published in The Tan Sheet

Executive Summary

Upcoming promotions for Novartis Consumer Health's Benefiber supplement likely will focus on the product's "grit-free" and "non-thickening" attributes rather than specific performance claims

You may also be interested in...



Psyllium seed husk/heart disease health claim for food approved.

PSYLLIUM SEED HUSK/HEART DISEASE CLAIM FOR FOOD APPROVED by FDA in a final rule published in the Federal Register Feb. 18 and effective immediately. The agency is amending current food labeling regulations to allow foods containing soluble fiber from psyllium seed husk, when included as part of a diet low in saturated fat and cholesterol, to bear labeling claiming a link to a reduction of the risk of coronary heart disease (CHD). Soluble fiber from psyllium seed husk has been shown in studies to lower blood total and LDL ("bad") cholesterol.

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS093500

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel